Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.32 |
| ▸ | LDHA | P00338 | 2/20 | 0.32 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | LDHB | P07195 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988555 | 0.86 | KMT2A (0.33) | PDE5ALDHAGAAKMT2ALDHB | |
| SCHEMBL3988514 | 0.86 | QPCTL (0.33) | PDE5AQPCTL | |
| SCHEMBL5880784 | 0.86 | LDHA (0.38) | LDHAKMT2ALDHBOPRD1 | |
| SCHEMBL5880970 | 0.85 | PDE4A (0.34) | PDE5ALDHALMNALDHBOPRD1 | |
| SCHEMBL3987507 | 0.83 | LDHA (0.40) | LDHALDHB | |
| SCHEMBL3990626 | 0.83 | ALDH1A1 (0.36) | PDE5ALDHALMNALDHB | |
| SCHEMBL3988195 | 0.83 | NPC1 (0.37) | PDE5ALDHAGAALDHB | |
| SCHEMBL5880717 | 0.83 | FOXO1 (0.38) | GAAKMT2A | |
| SCHEMBL5880892 | 0.82 | MAPT (0.34) | PDE5ALDHAGAAOPRD1 | |
| SCHEMBL3992476 | 0.82 | PDE2A (0.34) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | PDE5A 1964/4885LDHA 2373/4885SLK 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.